GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sernova Biotherapeutics Inc (FRA:PSH0) » Definitions » Capex-to-Operating-Cash-Flow

Sernova Biotherapeutics (FRA:PSH0) Capex-to-Operating-Cash-Flow : 0.00 (As of Jan. 2025)


View and export this data going back to 2014. Start your Free Trial

What is Sernova Biotherapeutics Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Sernova Biotherapeutics's Capital Expenditure for the three months ended in Jan. 2025 was €0.00 Mil. Its Cash Flow from Operations for the three months ended in Jan. 2025 was €-3.24 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


Sernova Biotherapeutics Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Sernova Biotherapeutics's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sernova Biotherapeutics Capex-to-Operating-Cash-Flow Chart

Sernova Biotherapeutics Annual Data
Trend Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Sernova Biotherapeutics Quarterly Data
Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Sernova Biotherapeutics's Capex-to-Operating-Cash-Flow

For the Biotechnology subindustry, Sernova Biotherapeutics's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sernova Biotherapeutics's Capex-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sernova Biotherapeutics's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Sernova Biotherapeutics's Capex-to-Operating-Cash-Flow falls into.


;
;

Sernova Biotherapeutics Capex-to-Operating-Cash-Flow Calculation

Sernova Biotherapeutics's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Oct. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / -12.609
=N/A

Sernova Biotherapeutics's Capex-to-Operating-Cash-Flow for the quarter that ended in Jan. 2025 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / -3.241
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sernova Biotherapeutics  (FRA:PSH0) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Sernova Biotherapeutics Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Sernova Biotherapeutics's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Sernova Biotherapeutics Business Description

Traded in Other Exchanges
Address
700 Collip Circle, Suite 114, London, ON, CAN, N6G 4X8
Sernova Biotherapeutics Inc is a clinical-stage company developing regenerative medicines. The company develops Cell Pouch with human donor cells or stem cells to create a biohybrid organ. The Cell Pouch is a implantable medical device designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells, which then release proteins, hormones, or other factors into the bloodstream for the long-term treatment of multiple chronic diseases such as type 1 diabetes, hypothyroid disease, and rare diseases such as hemophilia A.

Sernova Biotherapeutics Headlines

No Headlines